JenaValve Technology, Inc., developer and manufacturer of the Trilogy™ Transcatheter Heart Valve (THV) System, today announced that patient enrollment has begun in the ARTIST study, an RCT evaluating ...

IRVINE, Calif., July 14, 2025 (GLOBE NEWSWIRE) -- JenaValve Technology, Inc., developer and manufacturer of the TrilogyTM Transcatheter Heart Valve (THV) System, today announced that patient ...

In the first placebo-controlled study of vaporized cannabis for acute migraine, patients report greater relief from pain and ...

Dosing of the first patient in Phase 2b marks an important transition of the RESOLVE trial from a Phase 2a open-label study ...

Suven Life Sciences has a portfolio of advanced-stage clinical candidates and research programs designed for CNS disorders ...

After 12 weeks of treatment, 75% of per-protocol patients receiving 0.05% urcosimod showed greater than 80% reduction in ...

A Mediterranean diet improved adherence and modestly reduced weight in older African American adults but did not enhance ...

Digital business training offers flexibility and scalability, but translating these features into tangible benefits for women ...

In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in ...

A trial testing a nerve-sparing (NeuroSAFE) technique in radical prostatectomy may improve patient-reported outcomes.

Vibration therapy eases fatigue and improves motor and cognitive outcomes in MS, outperforming standard physical exercise ...

Penumbra, Inc. (NYSE:PEN) is one of the 11 Best Mid-cap Healthcare Stocks to Buy According to Hedge Funds. The company ...